In vitro evaluation of the potential for drug-induced toxicity based on 35S-labeled glutathione adduct formation and daily dose

Bioanalysis

Volumn 4, Issue 3, 2012, Pages 263-269

  Miyaji, Yoshihiro ^a   Makino, Chie ^a   Kurihara, Atsushi ^a   Suzuki, Wataru ^a   Okazaki, Osamu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CELECOXIB; DONEPEZIL; EBROTIDINE; GLUTATHIONE; ISAXONINE; LEVOFLOXACIN; NIPEROTIDINE; OLMESARTAN; PIOGLITAZONE; PIPERANOMETOZINE; RITONAVIR; ROSIGLITAZONE; SULFUR 35; TILBROQUINOL; TROVAFLOXACIN;

ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG EFFECT; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; METABOLITE; RADIOMETRY; TOXICITY TESTING;

DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; SULFUR RADIOISOTOPES; TICLOPIDINE;

EID: 84856816691     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.316     Document Type: Article

References (27)

1. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the 'multiple determinant hypothesis' for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142, 7-23 (2002). (Pubitemid 35232550)
2. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy. Clin. Immunol. 3, 235-242 (2003). (Pubitemid 37010877)
3. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499 (2005). (Pubitemid 40861991)
4. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004). (Pubitemid 38134055)
5. Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37, 41-213 (2005). (Pubitemid 40259715)
6. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361 (2005). (Pubitemid 40691298)
7. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the 'danger hypothesis' and innate immune system. Chem. Res. Toxicol. 12, 387-395 (1999). (Pubitemid 29352401)
8. Takakusa H, Masumoto H, Yukinaga H et al. Covalent binding and tissue distribution/ retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab. Dispos. 36, 1770-1779 (2008).
9. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21, 1814-1822 (2008).
10. Bauman JN, Kelly JM, Tripathy S et al. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 22, 332-340 (2009).
11. Nakayama S, Atsumi R, Takakusa H et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 37, 1970-1977 (2009).
12. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 37, 2383-2392 (2009).
13. Baillie TA, Davis MR. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass. Spectrom. 22, 319-325 (1993). (Pubitemid 23165443)
14. Gan J, Harper TW, Hsueh MM, Qu Q, Humphreys WG. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18, 896-903 (2005). (Pubitemid 40705457)
15. Masubuchi N, Makino C, Murayama N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20, 455-464 (2007). (Pubitemid 46548692)
16. Takakusa H, Masumoto H, Makino C, Okazaki O, Sudo K. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab. Pharmacokinet. 24, 100-107 (2009).
17. Gan J, Ruan Q, He B, Zhu M, Shyu WC, Humphreys WG. In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol. 22, 690-698 (2009).
18. Reese M, Sakatis M, Ambroso J et al. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem. Biol. Interact. 192, 60-64 (2011).
19. Thompson RA, Isin EM, Li Y et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem. Biol. Interact. 192, 65-71 (2011).
20. Masubuchi Y, Nakano T, Ose A, Horie T. Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch. Toxicol. 75, 538-543 (2001). (Pubitemid 33044112)
21. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290, 1116-1125 (1999). (Pubitemid 29400251)
22. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28, 1031-1037 (2000). (Pubitemid 30660356)
23. Koudriakova T, Iatsimirskaia E, Utkin I et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26, 552-561 (1998). (Pubitemid 28498361)
24. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32, 863-878 (2002). (Pubitemid 35155521)
25. Kassahun K, Skordos K, McIntosh I et al. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic a,b-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem. Res. Toxicol. 18, 1427-1437 (2005). (Pubitemid 41361716)
26. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos. 31, 1352-1360 (2003). (Pubitemid 37310324)
27. Kent UM, Juschyshyn MI, Hollenberg PF. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2, 215-243 (2001). (Pubitemid 32782795)